Profile data is unavailable for this security.
About the company
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company’s pipeline includes two clinical-stage synthetic lethality programs. Its lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small-molecule ATR inhibitor, both in clinical development for solid tumor indications. Its ATRN-119 is an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR). The ATR kinase is a master regulator of Deoxyribonucleic Acid (DNA) damage response, with roles in cell cycle control and DNA repair following replication stress. It is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute. It also has an early-stage program, in the lead optimization stage, for an undisclosed DNA-damage response (DDR) target.
- Revenue in USD (TTM)488.24k
- Net income in USD-13.04m
- Incorporated2019
- Employees8.00
- LocationAprea Therapeutics Inc3805 OLD EASTON ROADDOYLESTOWN 18902United StatesUSA
- Phone+1 (215) 948-4119
- Fax+1 (302) 655-5049
- Websitehttps://www.aprea.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Matinas BioPharma Holdings Inc | 0.00 | -16.87m | 3.78m | 3.00 | -- | 0.539 | -- | -- | -3.30 | -3.30 | 0.00 | 1.09 | 0.00 | -- | -- | 0.00 | -111.43 | -49.82 | -126.56 | -54.00 | -- | -- | -- | -2,545.33 | -- | -- | 0.0025 | -- | -100.00 | -- | -5.71 | -- | -- | -- |
| Nymox Pharmaceutical Corp | -100.00bn | -100.00bn | 3.80m | 3.00 | -- | -- | -- | -- | -- | -- | -- | -0.0717 | -- | -- | -- | -- | -- | -397.74 | -- | -- | -- | -- | -- | -883,740.00 | -- | -- | -- | -- | -- | -- | 49.21 | -- | -- | -- |
| Mosaic Immunoengineering Inc | 0.00 | -671.75k | 3.83m | 2.00 | -- | -- | -- | -- | -0.0928 | -0.0928 | 0.00 | -1.01 | 0.00 | -- | -- | 0.00 | -1,410.50 | -- | -- | -- | -- | -- | -- | -- | -- | -7.37 | -- | -- | -- | -- | 8.56 | -- | -- | -- |
| Revelation Biosciences Inc | 0.00 | -14.08m | 3.86m | 8.00 | -- | 0.1198 | -- | -- | -120.02 | -120.02 | 0.00 | 12.27 | 0.00 | -- | -- | 0.00 | -82.96 | -- | -118.88 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12,406.06 | -- | -- | -- |
| Silo Pharma Inc | 72.12k | -5.08m | 3.88m | -- | -- | 0.6078 | -- | 53.74 | -0.9262 | -0.9262 | 0.0117 | 0.4788 | 0.0097 | -- | -- | -- | -67.91 | -29.61 | -76.93 | -32.10 | 65.24 | 92.17 | -7,039.37 | -3,630.72 | -- | -- | 0.00 | -- | 0.00 | 12.19 | -20.98 | -- | -- | -- |
| Clearside Biomedical Inc | 3.33m | -26.00m | 3.92m | 32.00 | -- | -- | -- | 1.18 | -5.06 | -5.06 | 0.6461 | -10.31 | 0.1632 | -- | 6.32 | 104,031.30 | -127.43 | -67.79 | -160.28 | -84.94 | 88.07 | -- | -780.90 | -241.58 | -- | -- | 8.48 | -- | -79.77 | -5.20 | -5.75 | -- | 108.16 | -- |
| Indaptus Therapeutics Inc | 0.00 | -16.87m | 3.95m | 7.00 | -- | 0.6274 | -- | -- | -31.67 | -31.67 | 0.00 | 2.81 | 0.00 | -- | -- | 0.00 | -223.71 | -56.08 | -317.86 | -68.84 | -- | -- | -- | -- | -- | -13.74 | 0.00 | -- | -- | -- | 2.60 | -- | -- | -- |
| Galmed Pharmaceuticals Ltd | 0.00 | -8.70m | 4.03m | 3.00 | -- | 0.1757 | -- | -- | -3.60 | -3.60 | 0.00 | 3.49 | 0.00 | -- | -- | 0.00 | -40.91 | -55.02 | -46.34 | -64.19 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.75 | -- | -- | -- |
| ENDRA Life Sciences Inc | 0.00 | -8.01m | 4.09m | 21.00 | -- | 16.12 | -- | -- | -13.35 | -13.35 | 0.00 | 0.2178 | 0.00 | -- | -- | 0.00 | -154.83 | -132.71 | -183.46 | -155.93 | -- | -- | -- | -- | 1.31 | -- | 0.00 | -- | -- | -- | -14.39 | -- | -18.17 | -- |
| Aprea Therapeutics Inc | 488.24k | -13.04m | 4.26m | 8.00 | -- | 0.3339 | -- | 8.73 | -2.14 | -2.14 | 0.08 | 1.95 | 0.0237 | -- | -- | 61,030.00 | -63.27 | -81.97 | -74.72 | -94.17 | -- | -- | -2,670.56 | -11,051.52 | -- | -- | 0.00 | -- | 157.63 | -- | 9.30 | -- | -12.91 | -- |
| Cannabis Bioscience Internatnl Hlgs Inc | 148.34k | -555.16k | 4.65m | 2.00 | -- | -- | -- | 31.35 | -0.00006 | -0.00006 | 0.00001 | -0.0001 | 4.55 | -- | 11.35 | 74,170.00 | -1,702.42 | -652.66 | -- | -- | 73.11 | 87.76 | -374.25 | -177.59 | -- | -4.30 | -- | -- | 21.77 | 0.8662 | 15.74 | -- | -- | -- |
| Genprex Inc | 0.00 | -17.05m | 4.68m | 15.00 | -- | 2.64 | -- | -- | -52.85 | -52.85 | 0.00 | 0.7646 | 0.00 | -- | -- | 0.00 | -448.99 | -100.44 | -1,253.41 | -109.71 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 30.69 | -- | -- | -- |
| Decoy Therapeutics Inc | 0.00 | -5.00m | 4.72m | 2.00 | -- | 0.1643 | -- | -- | -39.19 | -39.19 | 0.00 | 4.50 | 0.00 | -- | -- | 0.00 | -100.54 | -73.17 | -139.55 | -84.56 | -- | -- | -- | -987.44 | -- | -- | 0.00 | -- | -- | -- | 55.55 | -- | -- | -- |
| Bio Green Med Solution Inc | 81.00k | -6.97m | 4.81m | 12.00 | -- | 0.4835 | -- | 59.32 | -80.13 | -80.13 | 0.0775 | 2.03 | 0.012 | -- | 0.0821 | -- | -80.35 | -65.34 | -175.85 | -83.85 | 20.99 | -- | -6,714.82 | -17,774.73 | 5.07 | -241.39 | 0.00 | -- | -89.76 | -- | 50.73 | -- | -- | -- |
| Bioxytran Inc | 0.00 | -2.11m | 4.81m | 2.00 | -- | -- | -- | -- | -0.0235 | -0.0235 | 0.00 | -0.0326 | 0.00 | -- | -- | -- | -1,340.44 | -1,468.56 | -- | -- | -- | -- | -- | -- | -- | -1.99 | -- | -- | -- | -- | 47.08 | -- | -- | -- |
| Cyclerion Therapeutics Inc | 2.86m | -2.20m | 4.91m | 1.00 | -- | 0.4843 | -- | 1.72 | -0.7587 | -0.7587 | 1.00 | 2.58 | 0.2957 | -- | 39.65 | 2,855,000.00 | -22.77 | -53.70 | -24.80 | -63.57 | -- | -- | -77.02 | -1,913.83 | -- | -- | 0.00 | -- | -- | -15.00 | 75.72 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to Aprea Therapeutics Inc's reporting currency: US Dollar USD
20.30%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| AIGH Capital Management LLCas of 31 Dec 2025 | 370.54k | 5.30% |
| Sphera Funds Management Ltd.as of 30 Sep 2025 | 270.00k | 3.86% |
| Nantahala Capital Management LLCas of 31 Dec 2025 | 205.76k | 2.94% |
| DAFNA Capital Management LLCas of 30 Sep 2025 | 137.17k | 1.96% |
| DRW Securities LLCas of 31 Dec 2025 | 120.65k | 1.73% |
| Sio Capital Management LLCas of 30 Sep 2025 | 112.22k | 1.61% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 76.95k | 1.10% |
| Jane Street Capital LLCas of 31 Dec 2025 | 46.62k | 0.67% |
| Geode Capital Management LLCas of 31 Dec 2025 | 40.95k | 0.59% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 38.46k | 0.55% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
